Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled TrialSammy Huygens, Jarom Heijmans, Quincy Hofsink et al.|The Journal of Infectious Diseases|2022Cited by 27
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patientsSammy Huygens, Bart Rijnders, P. Martin van Hagen et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 23
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort StudySammy Huygens, Bas B. Oude Munnink, Marion Koopmans et al.|Clinical Infectious Diseases|2024Cited by 15
SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trialSammy Huygens, Jarom Heijmans, Bart Rijnders et al.|medRxiv|2022Cited by 1